Loading…
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $84M | $-267M | $-264M | $-263M | -49.1% | 54.0% | - |
| 2024 | $55M | $-197M | $-194M | $-182M | -36.7% | -29.1% | - |
| 2023 | $77M | $-141M | $-144M | $-90M | -71.8% | 99.3% | - |
| 2022 | $39M | $-173M | $-180M | $-172M | -59.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 38.63 | 76.99 | 54.55 | 83.98 |
| Operating Expense | 222.49 | 232.05 | 267.58 | 369.65 |
| Operating Income | -183.87 | -155.06 | -213.03 | -285.67 |
| EBITDA | -173.06 | -141.41 | -196.60 | -266.81 |
| EBIT | -183.87 | -155.06 | -213.03 | -285.67 |
| Pretax Income | -180.36 | -143.95 | -193.30 | -263.70 |
| Tax Provision | 0 | 0 | 0.27 | 0.76 |
| Net Income | -180.36 | -143.95 | -193.57 | -264.46 |
| Net Income Common Stockholders | -180.36 | -143.95 | -193.57 | -264.46 |
| Total Expenses | 222.49 | 232.05 | 267.58 | 369.65 |
| Interest Income | 3.51 | 11.12 | 19.73 | 21.97 |
| Research And Development | 184.50 | 189.15 | 221.63 | 316.90 |
| Selling General And Administration | 38 | 42.90 | 45.94 | 52.74 |
| Normalized EBITDA | -173.06 | -141.41 | -196.60 | -266.81 |
| Normalized Income | -180.36 | -143.95 | -193.57 | -264.46 |
| Basic EPS | -3.71 | -2.65 | -2.88 | 0 |
| Diluted EPS | -3.71 | -2.65 | -2.88 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -180.36 | -143.95 | -193.57 | -264.46 |
| Reconciled Depreciation | 10.81 | 13.65 | 16.43 | 18.86 |
| Net Interest Income | 3.51 | 11.12 | 19.73 | 21.97 |
| Net Income From Continuing And Discontinued Operation | -180.36 | -143.95 | -193.57 | -264.46 |
| Total Operating Income As Reported | -183.87 | -155.06 | -213.03 | -285.67 |
| Diluted Average Shares | 48.61 | 54.34 | 67.12 | 0 |
| Basic Average Shares | 48.61 | 54.34 | 67.12 | 0 |
| Diluted NI Availto Com Stockholders | -180.36 | -143.95 | -193.57 | -264.46 |
| Net Income Including Noncontrolling Interests | -180.36 | -143.95 | -193.57 | -264.46 |
| Net Income Continuous Operations | -180.36 | -143.95 | -193.57 | -264.46 |
| Net Non Operating Interest Income Expense | 3.51 | 11.12 | 19.73 | 21.97 |
| Interest Income Non Operating | 3.51 | 11.12 | 19.73 | 21.97 |
| General And Administrative Expense | 38 | 42.90 | 45.94 | 52.74 |
| Other Gand A | 38 | 42.90 | 45.94 | 52.74 |
| Operating Revenue | 38.63 | 76.99 | 54.55 | 83.98 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Nurix Therapeutics, Inc.this co. | NRIX | $1.7B | - | 3.57 | -49.1% | -4.02 |
| Sonida Senior Living, Inc. | SNDA | $1.8B | - | -37500.00 | -125.8% | 57.41 |
| Harmony Biosciences Holdings, Inc. | HRMY | $1.8B | 11.23 | 2.05 | 18.2% | 4.68 |
| Palvella Therapeutics, Inc. | PVLA | $1.8B | - | 54.18 | -149.1% | - |
| Recursion Pharmaceuticals, Inc. | RXRX |
| $1.7B |
| - |
| 1.54 |
| -57.0% |
| -1.91 |
| Amylyx Pharmaceuticals, Inc. | AMLX | $1.7B | - | 5.62 | -47.4% | -9.25 |
| Sionna Therapeutics, Inc. | SION | $1.7B | - | 5.46 | -24.5% | -16.50 |
| Agios Pharmaceuticals, Inc. | AGIO | $1.7B | - | 1.37 | -34.6% | -1.37 |
| Astrana Health, Inc. | ASTH | $1.6B | 83.54 | 2.41 | 2.9% | 18.68 |
| Peer Median | - | 47.39 | 2.23 | -41.0% | -1.37 | |